Anti-annexin a2 monoclonal antibodies

A monoclonal antibody, antibody technology, applied in the direction of antibody, anti-animal/human immunoglobulin, immunoglobulin, etc.

Active Publication Date: 2019-05-21
AGENCY FOR SCI TECH & RES
View PDF4 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006]To date, there are no anti-ANXA2 monoclonal antibodies available for antibody therapy or as antibody-drug conjugates for cancer therapy
Furthermore, antibodies targeting unique cancer-specific glycoforms of ANXA2 have not been reported

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-annexin a2 monoclonal antibodies
  • Anti-annexin a2 monoclonal antibodies
  • Anti-annexin a2 monoclonal antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0122]Non-limiting examples of the present invention, including the best mode and comparative examples, will be further described in more detail by reference to specific examples, which should not be construed as limiting the scope of the invention in any way.

[0123] Materials and methods

[0124] Antibody production and purification

[0125] Using Choo et al. (Choo AB, Tan HL, Ang SN, Fong WJ, Chin A, Lo J, et al. Selection against undifferentiated human embryonic stem cells by acytotoxic antibody recognizing podocalyxin-like protein-1. Stem Cells DaytOhio.2008; 26 :1454–63) to produce monoclonal antibodies 2448 and C51 by whole-cell immunization of human embryonic stem cells (HES-3) using the mouse hybridoma technique reported. . Hybridomas were kept at 37°C with 5% CO 2 ClonaCell in a humid incubator TM - in HY medium E (Stem Cells Technologies). Chimeric (including afucosylated) antibodies are expressed in DG44-CHO cells and maintained in BTI's proprietary serum...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to an antigen-binding protein, preferably a monoclonal antibody, against annexin A2 (ANXA2), comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequenceGYSITSGYSWH, a VHCDR2 of sequence YIHYSGSTKYNPSLKS and a VHCDR3 of sequence GSNYGFDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSNDQKNYLA, a VLCDR2 of sequence WASIRES, and a VLCDR3 of sequence QQYYIYPLT. Also provided is an ANXA2 binding protein comprising (i) a heavy chain variable domain comprising a VHCDR1 of sequence VYSITSGYSWH; a VHCDR2 of sequence YIHYSGSTKYNPSLKS, and a VHCDR3 of sequence GTDNAVDY; and (ii) a light chain variable domain comprising a VLCDR1 of sequence KSSQSLLYSSNQKNYLA, a VLCDR2 of sequence WASSRES, and a VLCDR3 of sequence QQYYIYPLT. The antibodies preferably bind to an N-linked glycan on ANXA2, and are internalised upon binding. They may be conjugated with cytotoxins and may be used in the treatment or detection of cancer.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority from Singapore Application No. 10201606178X filed on 26 July 2016, the contents of which are hereby incorporated by reference in their entirety for all purposes. field of invention [0003] The present invention generally relates to antibodies. Specifically, the present invention relates to anti-Annexin A2 monoclonal antibodies and uses thereof. Background technique [0004] Annexin A2 (ANXA2) is involved in a variety of cellular processes and clinical associations, notably the development of cancer. It is a calcium-dependent phospholipid-binding protein that functions to help organize exocytosis of intracellular proteins to the extracellular domain. ANXA2 is a pleiotropic protein, meaning its function depends on where and when in the body. [0005] Increased expression of ANXA2 is frequently observed in a broad spectrum of cancer cells. ANXA2 in acute lymphoblastic l...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/395C07K16/28G01N33/577A61P35/00
CPCA61P35/00G01N33/574G01N2333/4718A61K2039/505C07K2317/24C07K2317/54C07K2317/622C07K2317/73C07K2317/732C07K2317/734C07K2317/77C07K2317/90C07K2319/03C07K2319/33A61K47/6825A61K47/6843C07K16/18A61K31/282A61K31/337A61K31/5377A61K38/1774C07K14/7051A61K39/0011A61K2039/5156A61K2039/5158A61K47/6819A61K39/3955A61K2039/572C07K14/70521C07K2317/34C07K2317/40C07K2317/565C07K2319/30
Inventor S·柯徐文华陈行樑冯慧佳陈美仪梁文彦
Owner AGENCY FOR SCI TECH & RES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap